The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is underway in Chicago, featuring significant advancements in oncology research and treatment. Key highlights include Summit Therapeutics' experimental cancer drug, which decisively outperformed Merck's Keytruda in a Phase 3 lung cancer study conducted in China, resulting in a 270% surge in Summit's shares. Additionally, Pfizer unveiled new 5-year progression-free survival (PFS) data for lorlatinib, showing an 81% reduction in cancer progression compared to Xalkori in patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Guardant Health is presenting studies on its blood tests and real-world data to advance precision oncology and cancer screening. The Giants of Cancer Care program honored leading researchers, including Margaret Shipp, MD, and Carol Aghajanian, MD, for their contributions to oncology. AI-driven research and innovative treatments are also prominent at the event, with companies like Qure.ai and nference showcasing their latest advancements, with global clearances such as FDA and EU MDR CE varying across geographies.
Thank you to @aparna1024 of @MassGenBrigham for the interview on the HERKULES-3 trial of ERAS-007 plus encorafenib and cetuximab! Check out https://t.co/NFJ4GmvcEW for more coverage from #ASCO24 @ASCO #CRC https://t.co/dXLKp1ZyUk
1/n New med #lorlatinib gives patients with advanced lung cancer (including cases where it had already metastasized into the brain) previously unheard-of success against the cancer. It's an orally-taken inhibitor of ALK and ROS1 enzymes. https://t.co/cm55SxC5CS
Tweets & thread from #asco24 by @StanfordCancer's dir of melanoma program & dir of solid tumor cell therapy. In April, she was part of team who treated the 1st advanced melanoma patient globally w/the 1st FDA-approved cellular therapy 4 solid tumors—TILs. Amtagvi was… https://t.co/PladKyip2k
Thank you to Michael Deininger, MD, PhD, of @Versiti, for stopping by during #ASCO24 to talk about the 4-year results of the OPTIC trial of ponatinib in CP-CML! Head to our site to see more from the first day of @ASCO 2024! #leusm https://t.co/McEtwvjaJu https://t.co/iThPNXfDm2
Thank you to @AlGarfall of @PennMedicine for dropping in to discuss the MajesTEC-1 trial. Log on to https://t.co/NFJ4GmvcEW to see all of our coverage of #ASCO2024 #multiplemyeloma @ASCO https://t.co/b53GuwQIrH
We had the opportunity to interview @MikeSerzanMD of @DanaFarber on the ARCITECT study examining combination immunotherapy in #RCC Check out https://t.co/NFJ4GmvcEW for more coverage from #ASCO24 @ASCO https://t.co/gcVLPdUsdm
Don’t miss tonight’s first LIVE broadcast from #ASCO24! Register below for tonight's episode streaming at 7 PM CT featuring insights from Ben Levy and @Dr_Shella_SFL #leusm #lcsm @nyulangone @HopkinsMedicine @hopkinskimmel https://t.co/A9eD6SbZdR https://t.co/IO6qIq3T5c
Don’t miss tonight’s first LIVE broadcast from #ASCO24! Register below for tonight's episode streaming at 7 PM CT featuring insights from Ben Levy and #leusm @Dr_Shella_SFL #lcsm @nyulangone @HopkinsMedicine @hopkinskimmel https://t.co/A9eD6SbZdR https://t.co/l4QIEYGUyu
#AI assistive tool for #LungCancer screening improved specificity of radiologists in both US and Japan https://t.co/FeZhWUpaLf @ASCO #ASCO24 #cancer #OncoRad https://t.co/B8MzDZ0JKg
At #ASCO2024, the PCC event is a great opportunity to network and share insights today. Our team is on the ground and showcasing how our technology is revolutionizing cancer trial matching. Stay tuned for more updates and insights from #ASCO24! #MassiveBio #ClinicalTrials https://t.co/iVsKScghIo
ASCO 2024: Oncology expert @PDRennert gives an update on @BioAleta and previews some targets at #ASCO24. Full video: https://t.co/AVtUDknZeQ https://t.co/DCSDINVOH8
. @Novartis’ Scemblix could be headed for first-line use in chronic myeloid #leukaemia after outperforming TKI drugs in the ASC4FIRST study presented at #ASCO24. #oncology https://t.co/Y4uvIdJT08
Check out new data from LLS TAP partner @MorphoSys, presented by @RaajitRampal of @MSKCancerCenter at #ASCO24. Its investigational drug, in combo with standard treatment, shows promising results for people with myelofibrosis. @ASCO 🔎 Learn more 👉 https://t.co/vkzmmPk0Yp
Ivonescimab plus chemotherapy improved progression-free survival in patients with non-small cell lung cancer who progressed on treatment with EGFR-TKIs. #ASCO24 https://t.co/7j1GAr3r9L https://t.co/Il2EmpzsUN
At #ASCO24? Check out our page created for attendees. Get recent articles, find out when you can meet our editors, and get information on submitting your manuscripts to JAMA, @JAMAOnc, @JAMANetworkOpen, or our other Network journals https://t.co/jYIVrHEG3Z https://t.co/bCn8PY7g0I
Very cool: The oral drug Lorlatinib reduced progression of a specific type of advanced lung cancer by *81%*, in phase 3 trials, compared to an existing drug. 60% of patients survived 5 yrs without a progression in cancer, compared to 8% in the control. https://t.co/mWOnboNWjY
We're back! Hosts @CParkMD and @YLeyfman will be bringing FOUR nights of LIVE coverage from #ASCO24! Register below for tonight's episode streaming at 7 PM CT featuring insights from Ben Levy and @Dr_Shella_SFL @nyulangone @HopkinsMedicine @hopkinskimmel https://t.co/mWqPGIVaPA https://t.co/x0E1tqNcVY
Join leukemia specialist Dr. Raajit Rampal for an oral session at 3:09pm (CT) on Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, Allotransplant at the @ASCO's Annual Meeting. Learn more: https://t.co/IVtLkPzu56 #ASCO24 https://t.co/XF4coBglOj
Don't miss these MSK voices at #ASCO24. https://t.co/S3rzdmBj5x
Happening now: Join sarcoma oncologist Dr. Sandra D’Angelo (@sandrapdangelo) for an oral session titled "Immunotherapy in Sarcoma: Current Data and Promising Strategies" at @ASCO’s Annual Meeting. Learn more: https://t.co/ZW3QGTQDh2 #ASCO24 https://t.co/vi5R2d2k81
Don’t miss Dr. Gounder’s presentation at #ASCO24. ⬇️ https://t.co/hCmpm8JX57
ASCO 2024: @ApexOnco's @JacobPlieth previews #ASCO24. $MRUS $SMMT $IOVA $CRBU $AZN $GSK $GILD $VSTM Full video: https://t.co/qnirrtOwWy https://t.co/yZ3uUBN799
Stay up-to-date with the latest key developments from ASCO 2024. Check out our coverage: https://t.co/DSZwED3aXc
🎉#ASCO24 peeps🙌Come check out @releiter & me share our stories during @ASCO voices from 1-2p in grand ballroom S100. We welcome all your ❤️. @tomleblancMD @ASCOPres @jrgralow @DarcyBurbage @realbowtiedoc @fumikochino @crisbergerot @MSKCancerCenter @OncoAlert @PallOncCoP https://t.co/kZd6FUUmrD
Novartis study points to larger role for targeted leukemia drug https://t.co/x0sBn2r2zC $NVS by @NedPagliarulo
Researchers from @MayoCancerCare are set to present key research findings, including two late-breaking abstracts, during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 31-June 4. Learn more: https://t.co/GDfMGadxou
We’re delighted for Dr. Carol Aghajanian for receiving the @GiantsofCC award in #gynecologiccancer. #ASCO24 https://t.co/lCO7NKztcO
How Vas Narasimhan views a pair of readouts in @Novartis’ growth strategy. $NVS CEO speaks with BioCentury Editor in Chief @FishburnSimone on major data readouts for Scemblix and remibrutinib at #ASCO24 & #EAACI Congress. @EAACI_HQ @ASCO #CML https://t.co/rtd9qT24B1
Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform https://t.co/phq9HkG2b6 https://t.co/zWeC196R9H
Novartis study points to larger role for targeted leukemia drug https://t.co/QLhmPc9Cbb by @NedPagliarulo $NVS #ASCO2024
Today kicks off #ASCO24. Follow along on our social channels from May 31-June 4 for live updates, and check out a preview of some of our MSK experts in attendance: https://t.co/w5VurzwjNc https://t.co/qBTydLMYdP
HR = 0.19 That's remarkable. And this is not against a placebo. The $PFE study compared Lorbrena against Xalkori. Lorbrena is not a big drug for Pfizer's bottom line, but it certainly means a lot to patients with ALK-positive lung cancer. #ASCO24 https://t.co/DWICqug8V9
nference to Present AI-Driven Research at 2024 ASCO Annual Meeting https://t.co/DXFgv89aG5 https://t.co/OryVHzFhjt
We’re pleased to be presenting 16 abstracts at #ASCO24 that demonstrate the power of our molecular profiling tests and multimodal data, featuring new data from our MRD assay, xM. Learn more: https://t.co/RF0zG9LJMu https://t.co/vZBi32Zf8G
Which company will present first-in-human data for ADC M9140 in heavily pretreated patients with metastatic colorectal cancer at @ASCO 2024? #ASCO24 #LARVOL #Oncology #CancerReseach
BREAKING: Today at #ASCO24, we unveiled new 5-year progression-free survival data in previously untreated, ALK+ advanced non-small cell #LungCancer (NSCLC): https://t.co/3ILg5Dymou https://t.co/PVsGiIMsKA
Asciminib Bests Standard-of-Care TKIs in Ph+ CML @ASCO @GCC_Cortes #ASCO24 #leusm #oncology #MedTwitter https://t.co/1o8gcnUYPA
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024 https://t.co/0n9RsWwISL https://t.co/PEQpCeUxGn
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC @ASCO @bensolomon1 #ASCO24 #lcsm #oncology #MedTwitter https://t.co/mrzCs1IE1i
Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO https://t.co/qmfmEekXiU https://t.co/BVa2ZCIPtE
First #ASCO24 story: Scemblix could set new standard in front-line leukaemia $NVS via @ApexOnco https://t.co/MsRVXyeL6J
Congratulations to the @GiantsofCC awardees, including Dr. Carol Aghajanian. #ASCO24 https://t.co/SwVtEvrujh
That’s a wrap on the 2024 Giants of Cancer Care Awards Ceremony! Congratulations to all of this year’s inductees! Nominations for the 2025 Giants of Cancer Care awards are officially open. See you next year! #GiantsCC24 https://t.co/tWfhSQLrZi
Take a look at our Class of 2024 Giants of Cancer Care along with previous inductees! What a wonderful night to remember. #GiantsCC24 https://t.co/V9jVI6WsaQ
From Chicago: The chief medical officer of @AstellasUS previews #ASCO24 and talks bout new modalities and targets the company has been working on. Full video: https://t.co/UUtahyyDuc https://t.co/tVM70OMWQn
Congratulations to @rweichselbaum for receiving the #GiantsCC24 award in Radiation Oncology! https://t.co/6iLze2XpuY
We would like to extend a tremendous congratulations to Vincent T. DeVita Jr, MD for receiving the #GiantsCC24 Visionary Award! https://t.co/RrS6kOhq25
A heartfelt congratulations to @marshalj23 for his #GiantsCC24 induction in Gastrointestinal Cancer! https://t.co/AlKm19EGXW
We are excited to congratulate @FAndreMD for his #GiantsCC24 award in Translational Science! https://t.co/rWiP5DLi5B
We would like to congratulate @EthanBasch1 for his Supportive, Palliative, and/or Geriatric Care award at #GiantsCC24! https://t.co/Xu37qMojG6
A sincere congratulations to Ching-Hon Pui, MD of @StJudeResearch for the 2024 Giants of Cancer Care award in Pediatric Oncology! #pedcsm https://t.co/IJLP6DH68q
Congratulations to @Rfonsi1 on being inducted into the Giants of Cancer Care Class of 2024 in Myeloma! #GiantsCC24 #mmsm https://t.co/mswCEZYsab
Congratulations to Lynn M. Schuchter, MD on her #GiantsCC24 induction for Melanoma & Other Skin Cancers. #melsm https://t.co/fIRbwyvRVC
We are excited to congratulate Margaret A. shipp, MD for her #GiantsCC24 induction in Lymphoma. #lymsm https://t.co/eNPm4nwTzx
We are happy to congratulate Carol Aghajanian, MD of @MSKCancerCenter for her award in Gynecologic Cancer at #GiantsCC24. https://t.co/Cb0IguraD5
Congratulations to Christopher Logothetis, MD on his induction to the class of #GiantsCC24 for Genitourinary Cancer! https://t.co/Eq8EsqEixJ
We are excited to congratulate @DrEdKim of @cityofhope on his #GiantsCC24 award in Community Outreach/Education! https://t.co/jcWQaa5c9v
The bispecific for whose rights Summit paid Akeso $500M in a 2022 deal has scored a head-to-head victory against Merck's Keytruda in a China-only lung cancer study, as Western studies continue to progress https://t.co/qEjt2EjaHS
Summit reaps benefit of Akeso deal as bispecific beats Keytruda head-to-head in China-only NSCLC study. @BioBonanos has details on the readout in @BioCentury. Shares up 270%. Look for Akeso to fly out of the gate in a few hours in HK. https://t.co/XNMynMIqA5
We’re here at Adler Planetarium for the 2024 Giants of Cancer Care awards presentation! Looking forward to seeing The Giants. #GiantsCC24 https://t.co/O6HNNvNTmw
Summit Therapeutics said on Thursday its experimental therapy to treat patients with a type of lung cancer met the main goal of a late-stage study conducted in China, sending its shares soaring 177%. https://t.co/DrnBS5QnpI https://t.co/DrnBS5QnpI
Hours before #ASCO24 kicks off, Bob Duggan's small biotech Summit may have stolen the show. Its experimental cancer drug topped Keytruda in a Phase 3 lung cancer study — but there's a major, China-related caveat to note. More here on $SMMT: https://t.co/KsCVhvyP9m
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance https://t.co/g83Ak9JQzv https://t.co/Rj2WZTakGl
OncoNano Medicine To Present a Trials in Progress Poster for ON-5001 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting https://t.co/XxMRo3ZiC0 https://t.co/EA5BiyRJSQ
$SMMT PD-1 beats $MRK Keytruda in head to head trial Up 227% 1st Line NSCLC In China PFS not OS https://t.co/Z3vOrk2ajy
The #ASCO annual meeting kicks off tomorrow and STAT has you covered with all the news you can expect from Chicago this year. https://t.co/nFEYOCxClZ
We're thrilled to announce @MSKCancerCenter recipients of @ConquerCancerFd @ASCO awards! These awards honor outstanding oncology experts who are partnering with patients to accelerate lifesaving research and advance equitable care. Congrats! #ASCO24 https://t.co/zODlMJlUbw
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China https://t.co/SLZ6Xzs3lV https://t.co/icPj1EQt47
Don't miss @DanaFarber posters at #ASCO24! They showcase the latest #CancerResearch, innovative treatments, and breakthroughs from leading experts in oncology. Gain insights, connect with researchers, and stay ahead in the fight against cancer. #oncology https://t.co/iBxV7EvKEq
Taste the Future: AI, Precision Oncology, and Clinical Trials with @MassiveBio at @ASCO 24 - @DrBonillaOnc @skurnaz https://t.co/Afz0Pu8fdr #ASCO24 #Cancer #OncoDaily #Oncology #ClinicalTrials #CancerResearch https://t.co/FuEJMeViX0
ICYMI: We are anticipating TONIGHT'S 2024 Giants of Cancer Care reception in Chicago, where we will celebrate leading physicians and researchers in #oncology! Tune in at 7PM to follow along with us. Don’t miss it! #OncLive #MedTwitter https://t.co/E5LOd0oiTe https://t.co/k5pPLDmxvb
Get ready for ASCO! Our new video series, The Show and After Show, previews data we're excited about and shares some opinions on what to do around town. Watch the full episode here: https://t.co/Izxe7AcLfI We'll see you in Chicago! #Oncology #CancerResearch https://t.co/EpipkhIN0N
Congratulations to @danafarber Margaret Shipp, MD, who is an inductee of the 2024 Giants of Cancer Care program. The program honors the accomplishments of leading researchers and educators whose discoveries have propelled the field and set the groundwork for future advancements. https://t.co/xx0KLs8Ol6
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening https://t.co/yBHuWby0zF https://t.co/gZ1xMR8kKS
News alert! To further the fight against #lungcancer, https://t.co/cqbZkTzXSl will unveil its #Al-powered Lung Cancer Continuum at #ASCO24 this week in Chicago. https://t.co/Vzt6tZabPg *Global clearances such as FDA and EU MDR CE vary across geographies. #AIInHealthcare
If you're heading out to #ASCO24 remember all @ApexOnco coverage will appear here -> https://t.co/JaKGDhbdPi Already includes our numerous preview stories.
As we're heading towards the @ASCO 2024, @LARVOL CLIN is excited to highlight the top influencers from over 2,500 leading oncologists on X. Discover more pre-ASCO 2024 insights: https://t.co/3WyMmNgDb5 #ASCO24 #LARVOL #Oncology #CancerResearch https://t.co/HVGAYRDVN9
NEJM Group's clinician-guides @JPatelMD, @ILSONDavid, Dr. Robert Dreicer, and @MikkaelSekeres preview the upcoming #ASCO24 meeting. Hear what oncology results they're looking forward to: https://t.co/9wkusnXLpu https://t.co/eFoxJKW1dM